Nasdaq: MPLT−73.66% 24h move
Price before$36.56Jul 24, 2026, 4:00 PM ET
First trade after$22.30Jul 27, 2026, 7:11 AM ET
24h later$9.63Jul 28, 2026, 7:05 AM ET
Complete Announced during: Premarket · announced Mon 7:07a ET (premarket); before = Fri close; first trade Mon 7:11a ET; time = SEC 8-K acceptance
MapLight Therapeutics (Nasdaq: MPLT) reported topline results from a Phase 2 trial of ML-007C in schizophrenia on July 27, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- ML-007C
- Treats
- Schizophrenia
- Phase
- Phase 2
- Result
- Met endpointThe trial met its primary endpoint, with the 210/3 mg twice-daily (BID) dose demonstrating a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at Week 5.
- Safety
- Safety and Tolerability ML-007C-MA was generally well tolerated across all doses studied.
- Sponsor
- MapLight Therapeutics Nasdaq: MPLT
- Dates
- Announced Jul 27, 2026, 7:07 AM ET (SEC 8-K filing time)
About this trial
This Phase 2 trial tested ML-007C in Schizophrenia. MapLight Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.2)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.